Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial -

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Endocrine system disorders
Summary
Final analysis of LATITUDE (n=1199) reported that overall survival was significantly longer with abiraterone acetate plus prednisone with androgen deprivation therapy (ADT) vs placebo with ADT (median 53·3 vs 36·5 months; HR 0·66; p<0·0001).
UKMi comment
A related commentary notes that these findings support the use of abiraterone acetate plus prednisone as early aggressive therapy for high-risk metastatic castration-sensitive prostate cancer.
Related links: Comment